Effectiveness of insulin degludec/liraglutide versus insulin degludec/insulin aspart in Japanese patients with type 2 diabetes

被引：0
|
作者：
Junko Oya
Tomoko Nakagami
Yukiko Hasegawa
Yuichiro Kondo
Aki Katamine
Mika Shimizu
Ryo Kubota
Rika Suda
Tetsuya Babazono
机构：
[1] Tokyo Women’s Medical University School of Medicine,Division of Diabetology and Metabolism, Department of Internal Medicine
来源：
Diabetology International | 2024年 / 15卷
关键词：
Type 2 diabetes; Insulin degludec/liraglutide; Insulin degludec/insulin aspart; HbA1c;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：237 / 243
页数：6
相关论文
共 50 条
  • [31] Insulin aspart/insulin degludec/insulin glargineLipoatrophy: case report
    [J]. Reactions Weekly, 2020, 1800 (1) : 170 - 170
  • [32] Efficacy and Safety of Insulin Aspart 30 and Insulin Degludec/Aspart vs. Basal Insulin in Patients with Type 2 Diabetes: A Meta-analysis
    Mishriky, Basem M.
    Tanenberg, Robert J.
    Cummings, Doyle M.
    [J]. DIABETES, 2017, 66 : A252 - A252
  • [33] Usefulness of Insulin Degludec in Japanese Type 1 Diabetes
    Suzuki, Jun
    Yamakawa, Tadashi
    Nagakura, Joe
    Shigematu, Erina
    Terauchi, Yasuo
    [J]. DIABETES, 2014, 63 : A231 - A231
  • [34] Liraglutide add-on to insulin degludec plus metformin vs addition of a single dose of insulin aspart to the largest meal in patients with Type 2 diabetes
    Russell-Jones, D.
    Mathieu, C.
    Rodbard, H. W.
    Cariou, B.
    Handelsman, Y.
    Philis-Tsimikas, A.
    Francisco, A. M. Ocampo
    Rana, A.
    Zinman, B.
    [J]. DIABETIC MEDICINE, 2014, 31 : 52 - 52
  • [35] Combination therapies in the management of type 2 diabetes: the use of insulin degludec/liraglutide
    Minze, Molly G.
    Chastain, Lisa M.
    [J]. THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2016, 12 : 471 - 478
  • [36] COST-EFFECTIVENESS OF INSULIN DEGLUDEC/INSULIN ASPART (IDEGASP) COMPARED WITH BIPHASIC INSULIN ASPART (BIASP 30) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS FROM A MEXICAN HEALTHCARE PERSPECTIVE
    Sanchez-Pedraza, V
    Hansen, B. B.
    Gundgaard, J.
    Uranga Romano, Garca J.
    Evans, M.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A672 - A672
  • [37] Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment
    Wysham, Carol
    Bajaj, Harpreet S.
    Del Prato, Stefano
    Franco, Denise Reis
    Kiyosue, Arihiro
    Dahl, Dominik
    Zhou, Chunmei
    Carr, Molly C.
    Case, Michael
    Goncalves, Livia Firmino
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2024,
  • [38] Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population
    Liu, Hongzhong
    Luo, Bin
    Chen, Xia
    Ingwersen, Steen H.
    Jia, Ting
    Jacobsen, Lisbeth Vestergard
    Hu, Pei
    [J]. JOURNAL OF DIABETES INVESTIGATION, 2022, 13 (04) : 652 - 656
  • [39] IDegAsp, a soluble insulin combination of ultra-long-acting insulin degludec and insulin aspart, in type 2 diabetes: comparison with biphasic insulin aspart 30
    Vaag, A.
    Leiter, L. A.
    Franek, E.
    Weng, J.
    Damci, T.
    Munoz Torres, M.
    Donnet, J. -P.
    Endahl, L.
    Skjoth, T.
    Niskanen, L.
    [J]. DIABETOLOGIA, 2011, 54 : S423 - S423
  • [40] Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose-lowering effects
    Haahr, Hanne
    Sasaki, Tomio
    Bardtrum, Lars
    Ikushima, Ippei
    [J]. JOURNAL OF DIABETES INVESTIGATION, 2016, 7 (04) : 574 - 580
12345